Source: International Congress 2017 – COPD management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
I. Savelikhina (Ivano-Frankivsk, Ukraine). The role of biomarkers and effectiveness of maintenance therapy in stable severe COPD. 1072

Member's Comments

No comment yet.

Related content which might interest you: The role of biomarkers in the management of severe asthma Source: International Congress 2019 – Severe asthma guidelines: update 2019 Year: 2019 The role of inflammatory biomarkers like precursors of COPD stability during long-term follow-up Source: International Congress 2019 – Research and innovation in airway diseases Year: 2019 Can we use a biomarker to guide antibiotic treatment in severe COPD exacerbations? Source: Breathe, 15 (4) 353; 10.1183/20734735.0257-2019 Year: 2019 Small airways function: evaluation in a population of adult patients with severe asthma and potential use as a response biomarker for anti-IL5 therapy Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Immunoproteasome function as a potential biomarker for asthma severity and response to therapy Source: Virtual Congress 2021 – Emerging new mechanisms of chronic lung disease Year: 2021 The effectiveness of early pulmonary rehabilitation in acute exacerbation of COPD in the terms of functional and systemic markers. Source: Virtual Congress 2020 – Reviews and novel insights into pulmonary rehabilitation Year: 2020 Identifying patients with severe asthma that will be benefit from biological therapy Source: Virtual Congress 2020 – Rethinking asthma Year: 2020 Formoterol turbuhaler is an effective maintenance and maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) irrespective of the level of lung function impairment and reversibility Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002 Preventing clinically important deterioration with single-inhaler triple therapy in COPD Source: ERJ Open Res, 4 (4) 00047-2018; 10.1183/23120541.00047-2018 Year: 2018 The relevance of respiratory muscle dysfunction and novel treatment options in COPD Source: International Congress 2017 – PG18 Targeting the locomotor and respiratory muscles in chronic obstructive pulmonary disease: novel interventional tools and rehabilitation strategies Year: 2017 A combinational approach to optimize biomarkers efficacy in identifying patients with sarcoidosis and monitoring respiratory functional worsening Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV Year: 2012 Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials Source: Eur Respir J, 53 (5) 1900599; 10.1183/13993003.00599-2019 Year: 2019 What is the role of prophylactic antibiotic therapy in chronic bronchitis or COPD? Source: Annual Congress 2009 - PG1 EU GRACE Network Full-day Course: vaccination and preventive measures for LRTIs in the community: what’s new? Year: 2009 Any role for cardiopulmonary exercise test as an outcome in severe asthmatic patients after the initiation of biological therapy? Source: Virtual Congress 2020 – From respiratory physiology to clinical practice: exercise and respiratory muscles Year: 2020 Early treatment response may predict long-term mepolizumab benefit in severe asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 QVA149 provides a rapid onset of action which is sustained throughout treatment in patients with COPD Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 The role of the individual rehabilitation programs in the complex treatment of the patients with bronchial asthma Source: Eur Respir J 2004; 24: Suppl. 48, 519s Year: 2004 Economic impact of delayed multiple-inhaler triple therapy initiation in COPD patients Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020